Details

Autor(en) / Beteiligte

• Pourmadadi, Mehrab
• Mohammadzadeh, Vahideh
• Sadat Mohammadi, Zahra
• Poorkhalili, Pegah
• Afjoul, Neda
• Behzadmehr, Razieh
• Fathi-Karkan, Sonia
• Rahdar, Abbas
• Ghotekar, Suresh

Titel

Advances in erlotinib delivery systems: Addressing challenges and exploring opportunities in EGFR-targeted cancer therapies

Ist Teil von

• Inorganic chemistry communications, 2024-03, Vol.161, p.112114, Article 112114

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• [Display omitted] •Researchers used polymer, lipid, and so on to decrease the side effects of erlotinib (ETB), an EGFR signaling pathway cancer medication.•Combination therapy systems improve therapeutic interventions' efficacy and safety.•A dual stimuli-responsive drug delivery system (DDS) was created using smart receptors-sensing chitosan nanoparticles and an aptamer AS1411 (APT) for pharmaceutical applications.•Carbon nanotubes, graphene, and fullerene are used in cancer treatment and medication delivery, with graphene oxide showing promise for ETB delivery.•Researchers made EGFR-mutant lung cancer tyrosine kinase inhibitor-resistant by delivering Endostar and Fedratinib to tumor locations. Cancer development in various organs, including the breast, ovary, brain, bladder, colon, and lung, is frequently connected to disturbances in the epidermal growth factor receptor (EGFR) signaling pathway. Erlotinib (ETB) has emerged as a specific therapeutic agent tackling this EGFR interruption, regulating tyrosine kinase activity, and preventing tumorigenesis. However, ETB's inhibition comes with side effects. This issue has been addressed by redefining the drug delivery system to perform as a drug carrier, greatly reducing the drug's toxicity. Various studies have recommended delivery strategies such as polymer, lipid, inorganic, and hybrid carriers to minimize side effects. The forthcoming study will delve deeper, exploring the environmental responsiveness and effectiveness of liposomal, polymer, and inorganic systems in delivering ETB, as well as the co-administration of ETB and a secondary drug. In addition, the information acquired underlines the valid strategy of targeting EGFR with small-molecule inhibitors in cancer therapy, like ETB, which is an approved EGFR inhibitor, further underscoring the relevance of this research. Foreseeing the necessity of a holistic overview of ETB nano delivery methods, we offered an updated perspective on ETB nano delivery systems with their current challenges and upcoming opportunities in this review article.